MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

MI-463

CAS No. : 1628317-18-9

MCE 站：MI-463

产品活性：MI-463是高效，有口服活性的menin-mLL相互作用的小分子抑制剂。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vitro: MI-463 can reach the target protein in mammalian cells and effectively inhibit the menin-mLL-AF9 interaction at sub-micromolar concentrations. Treatment of murine bone marrow cells (BMC) transformed with the mLL-AF9 oncogene with MI-463 results in substantial growth inhibition, with GI₅₀ of 0.23 μM.

In Vivo: MI-463 achieves high level in peripheral blood following a single intravenous or oral dose, while also showing high oral bioavailability (45%). Pharmacologic inhibition of the menin-mLL interaction substantially delays progression of mLL leukemia in murine models through on-target activity without causing toxicity. MI-463 induces strong inhibition of tumor growth with once daily intraperitoneal (i.p.) administration. The expression of mLL fusion protein target genes, HOXA9 and MEIS1, are significant reduced upon treatment with MI-463. 20 days treatment of MV4;11 xenograft recipient mice with MI-463 also results in a substantial delay in leukemia progression as manifested by a marked decrease in the bioluminescence level which is associated with a significant decrease in the population of leukemic cells in the peripheral blood, spleen and bone marrow samples.

相关产品：Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  A-485  |  Curcumin  |  Birabresib  |  C646  |  JQ-1 (carboxylic acid)  |  Anacardic Acid  |  I-BET151  |  SGC-CBP30  |  MG 149  |  KG-501  |  A-366  |  NSC 228155  |  CPI-203  |  PFI-1  |  IACS-9571 hydrochloride  |  ACBI1  |  GSK2801  |  MI-3  |  (+)-JQ1 PA  |  SGC-iMLLT  |  PF-CBP1 hydrochloride  |  Bromosporine  |  EML 425  |  MS436  |  GSK1379725A  |  GSK6853  |  HJB97  |  MS31 trihydrochloride  |  MS645  |  PROTAC BRD9 Degrader-1

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。